A Real World Study of Apatinib in Treatment of Patients With Gastric Carcinoma

Henan Cancer Hospital1 site in 1 country270 target enrollmentNovember 20, 2018

ConditionsGastric Carcinoma

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Gastric Carcinoma
Sponsor: Henan Cancer Hospital
Enrollment: 270
Locations: 1
Primary Endpoint: Overall Survival
Last Updated: 6 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The study was designed to evaluate the efficacy and safety of apatinib in the treatment of patients with gastric carcinoma.

Detailed Description

The study is a real-world non-interventional retrospective study and will collect the original medical records of patients with gastric carcinoma treated with apatinib from 2015 to 2018 in Henan Cancer Hospital. Clinical data such as patient demographic, history of treatments, tumor biological characteristics and adverse events will be analyzed to evaluate the efficacy and safety of apatinib and explore the risk factors of prognosis in patients with gastric carcinoma.

Registry

clinicaltrials.gov

Start Date

November 20, 2018

End Date

August 2020

Last Updated

6 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Henan Cancer Hospital

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Pathologically or cytologically confirmed gastric or residual gastric or gastroesophageal junction carcinoma;
•Patients received apatinib treatment at least once.